Transmission This article has some really cool pictures of some really really cool science. The study authors made a chemical/mechanical computer model of a virion inside an aerosol with water, lung fluid, mucous, and other crap that somebody might breathe out — 1.3 BILLION atoms worth — and then simulated it every millionth of a… Continue reading 2021-12-01 General
Category: Transmission
2021-11-30 General
Mitigation Measures This article describes tightened border controls in Canada in response to the threat of Omicron: Nigeria, Malawi and Egypt have been added to the list of restricted countries (South Africa, Mozambique, Namibia, Zimbabwe, Botswana, Lesotho and Eswatini were already on the list). Those who have been to any of their home countries in… Continue reading 2021-11-30 General
2021-11-23 General
Mitigation Measures I have heard that it is critically important for masks to fit well to be useful, yet most of the people I see wearing masks have big obvious gaps in them. How could these possibly work? And yet, clearly they do. In addition to multiple studies showing mask-wearing reduces cases, pretty much every… Continue reading 2021-11-23 General
2021-11-18 General
Treatments This article talks about the good long-term results of AstraZeneca’s polyclonal antibody (brand name Evusheld). The article says it’s a two shot therapy like a vaccine, and given pre-exposure gives 83% protection over six months, sort of like a vaccine. Unlike a vaccine, however, it should work just as well in people who are… Continue reading 2021-11-18 General
2021-10-30 to 11-01 General
Vaccines This preprint from Israel says that the vaccine effectiveness of a third dose of Pfizer vs. two doses of Pfizer at least five months ago was: 93% against hospitalization, 92% against severe disease (which I think is equivalent to “ICU” here), 81% against death. This article says that Novavax has finished its rolling review… Continue reading 2021-10-30 to 11-01 General
2021-10-28 General
Treatment This paper says that a single infusion of a new-to-me polyclonal antibody — sotrovimab — is 85% effective at preventing hospitalization when given early to high-risk COVID-19 patients. The FDA already gave an EUA to sotrovimab on 26 May; Canada gave interim approval on 30 July (and bought 10,000 doses on 4 October), so… Continue reading 2021-10-28 General
2021-10-27 General
Treatments Yay! This article says that Merck has licensed molnupiravir such that ~100 developing countries can manufacture it at low cost! This is awesome. (It hasn’t been approved by any countries yet, but it will be soon, I’m sure.) Yay yay! This article reports that a cheap mature drug for depression — fluvoxamine — reduces… Continue reading 2021-10-27 General
2021-10-23/24/25 General
Transmission In this small study of Italian health-care workers who were tested regularly, all of the people who tested positive but were asymptomatic tested negative the very next day. The mean time for the symptomatic patients to test negative was 11 days. Pathology This preprint says they found SARS-CoV-2 antibodies in the cerebrospinal fluid of… Continue reading 2021-10-23/24/25 General
2021-10-14 General
Vaccines Someone is live-tweeting the La Jolla Immunology Conference, and during a panel about an important paper from May that I’ve already talked about, they said something which I missed: that inter-individual variations in antibody responses are larger than the variations between responses to different variants. I’ve talked about the two-proline (2P) and six-proline (6P)… Continue reading 2021-10-14 General
2021-10-13 General
Diagnosis / Equity This Twitter thread suggests that the reason darker-skinned people have higher fatality rates from COVID-19 is because, well, they have darker skin: pulse oximeters, which are used to judge how serious a case is, don’t work on dark-skinned people. Economic effects This video from January 2021 makes the economic case — not… Continue reading 2021-10-13 General